Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Chronic Pain pipeline constitutes key companies continuously working towards developing Chronic Pain treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
Chronic Pain Overview
Chronic pain is long standing pain that persists beyond the usual recovery period or occurs along with a chronic health condition, such as arthritis. Chronic pain is longer in duration. It can be constant or intermittent. For example, headaches can be considered chronic pain when they continue over many months or years – even if the pain isn’t always present.
“Chronic Pain Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Chronic Pain Market.
The Chronic Pain Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Chronic Pain Pipeline Report:
- Companies across the globe are diligently working toward developing novel Chronic Pain treatment therapies with a considerable amount of success over the years. Chronic Pain Key players such as – Ribomic, BRIM Biotechnology, Oryn Therapeutics, GlaxoSmithKline, Peptinov, Kangstem Biotech, Celltex Therapeutics, Wuhan Createrna Science and Technology, Synact Pharma, OliPass Corporation, Selecta Biosciences, Mabion SA, Biosplice Therapeutics, and others, are developing therapies for the Chronic Pain treatment
- Chronic Pain Emerging therapies such as – RBM-010, BRM521, ORTD 1, GSK 3858279, PPV 06, FURESTEM-RA, Autologous Adiposederived Stem Cells, QR 052, AP1189, OLP 1002, SEL 212, MabionCD20, Lorecivivint, and others are expected to have a significant impact on the Chronic Pain market in the coming years.
- In November 2021, SynAct Pharma AB announced top-line results from thePhase IIa study of AP1189 in early rheumatoid arthritis (RA) patients experiencing severe disease activity.Patients treated with AP1189 achieved a mean reduction of 12.0 and 15.5 points in the 50 mg and 100 mg groups respectively, compared to 9.3 with placebo
- In September 2022, SynAct Pharma initiated a trial titled, “A Double-blind, Multi-center,Randomized, Placebo-controlled Study of the Safety and Efficacy of 12 Weeks Extended Treatment WithAP1189 in Early Rheumatoid Arthritis (RA) Patients naïve to DMARD Treatment”
Route of Administration
Chronic Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Chronic Pain Pipeline Therapeutics Assessment
- Chronic Pain Assessment by Product Type
- Chronic Pain By Stage and Product Type
- Chronic Pain Assessment by Route of Administration
- Chronic Pain By Stage and Route of Administration
- Chronic Pain Assessment by Molecule Type
- Chronic Pain by Stage and Molecule Type
DelveInsight’s Chronic Pain Report covers around products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Some of the key companies in the Chronic Pain Therapeutics Market include:
Eli Lilly and Company, Dickinson and Company, Medtronic plc, Johnson & Johnson, Novartis AG, AstraZeneca PLC, Becton, Bristol-Myers Squibb Company, and others
Emerging Chronic Pain Drugs Under Different Phases of Clinical Development Include:
- RBM-010: Ribomic
- BRM521: BRIM Biotechnology
- ORTD 1: Oryn Therapeutics
- GSK 3858279: GlaxoSmithKline
- PPV 06: Peptinov
- FURESTEM-RA: Kangstem Biotech
- Autologous Adiposederived Stem Cells: Celltex Therapeutics
- QR 052: Wuhan Createrna Science and Technology
- AP1189: Synact Pharma
- OLP 1002: OliPass Corporation
- SEL 212: Selecta Biosciences
- MabionCD20: Mabion SA
- Lorecivivint: Biosplice Therapeutics
Get a Free Sample PDF Report to know more about Chronic Pain Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/chronic-back-pain-pipeline-insight
Chronic Pain Pipeline Analysis:
The Chronic Pain pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Pain with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Pain Treatment.
- Chronic Pain key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Chronic Pain Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Pain market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Chronic Pain product details are provided in the report. Download the Chronic Pain pipeline report to learn more about the emerging Chronic Pain therapies
Chronic Pain Pipeline Market Drivers
- Increasing prevalence of various types of chronic pain, such as lower back pain, severe headache or migraine pain, and facial pain
- Growing geriatric population across the world
Chronic Pain Pipeline Market Barriers
- Addiction and toxicity associated with the drugs
- High cost associated with the treatment
Scope of Chronic Pain Pipeline Drug Insight
- Coverage: Global
- Key Chronic Pain Companies: Ribomic, BRIM Biotechnology, Oryn Therapeutics, GlaxoSmithKline, Peptinov, Kangstem Biotech, Celltex Therapeutics, Wuhan Createrna Science and Technology, Synact Pharma, OliPass Corporation, Selecta Biosciences, Mabion SA, Biosplice Therapeutics, and others
- Key Chronic Pain Therapies: RBM-010, BRM521, ORTD 1, GSK 3858279, PPV 06, FURESTEM-RA, Autologous Adipose Derived Stem Cells, QR 052, AP1189, OLP 1002, SEL 212, MabionCD20, Lorecivivint, and others
- Chronic Pain Therapeutic Assessment: Chronic Pain current marketed and Chronic Pain emerging therapies
- Chronic Pain Market Dynamics: Chronic Pain market drivers and Chronic Pain market barriers
Request for Sample PDF Report for Chronic Pain Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Chronic Pain Report Introduction |
|
2 |
Chronic Pain Executive Summary |
|
3 |
Chronic Pain Overview |
|
4 |
Chronic Pain- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Chronic Pain Pipeline Therapeutics |
|
6 |
Chronic Pain Late Stage Products (Phase II/III) |
|
7 |
Chronic Pain Mid Stage Products (Phase II) |
|
8 |
Chronic Pain Early Stage Products (Phase I) |
|
9 |
Chronic Pain Preclinical Stage Products |
|
10 |
Chronic Pain Therapeutics Assessment |
|
11 |
Chronic Pain Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Chronic Pain Key Companies |
|
14 |
Chronic Pain Key Products |
|
15 |
Chronic Pain Unmet Needs |
|
16 |
Chronic Pain Market Drivers and Barriers |
|
17 |
Chronic Pain Future Perspectives and Conclusion |
|
18 |
Chronic Pain Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report to know more about Chronic Pain drugs and therapies
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting